ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Options Flow

Live Options Flow

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P TSX Capped Composite...
35.07
0.46%
US Tech 100
17,244.80
1.57%
S&P 500
5,099.96
1.02%
US Dollar vs CAD
1.36805
0.00%
Bitcoin
63,446.97
-0.46%
Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Arvinas Inc (ARVN)

  7. Arvinas Inc (ARVN) News

ARVN Arvinas Inc

32.37
0.77 (2.44%)
Apr 26 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Stock Type
Arvinas Inc ARVN NASDAQ Common Stock
  Price Change Price Change % Share Price Last Trade
Upgrade Icon
0.77 2.44% 32.37 16:44:30
Open Price Low Price High Price Close Price Previous Close
31.73 31.04 32.72 32.37 31.60
more quote information »

Recent News

Date Time Source Heading
4/24/202415:30GLOBEArvinas Appoints Randy Teel, Ph.D., as Chief Business..
4/11/202406:00GLOBEArvinas Enters into a Transaction with Novartis, including a..
3/18/202415:40GLOBEArvinas Appoints Noah Berkowitz, M.D., Ph.D., as Chief..
3/04/202406:00GLOBEArvinas to Participate in Upcoming Investor Conferences
2/27/202417:35EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2/27/202417:34EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2/27/202417:33EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2/27/202417:33EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2/27/202415:46EDGAR2Form 10-K - Annual report [Section 13 and 15(d), not S-K..
2/27/202406:02EDGAR2Form 8-K - Current report
2/27/202406:00GLOBEArvinas Reports Fourth Quarter and Full Year 2023 Financial..
2/20/202415:06EDGAR2Form 8-K - Current report
2/20/202415:05GLOBEArvinas Announces Chief Financial Officer Transition
2/20/202406:00GLOBEArvinas Announces First-in-Human Dosing of ARV-102, an..
2/14/202407:00GLOBECarrick Therapeutics Announces First Patient Dosed in Phase..
2/13/202419:14EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
2/06/202405:45GLOBEArvinas and Pfizer’s Vepdegestrant (ARV-471) Receives FDA..
2/01/202415:30GLOBEArvinas to Present at 6th Annual Guggenheim Biotechnology..
1/16/202416:01GLOBEArvinas Appoints Jared Freedberg as General Counsel
1/16/202415:03EDGAR2Form S-8 - Securities to be offered to employees in employee..
1/08/202415:39EDGAR2Form 4 - Statement of changes in beneficial ownership of..
1/08/202406:45EDGAR2Form 8-K - Current report
12/08/202308:16EDGAR2Form S-3ASR - Automatic shelf registration statement of..
12/06/202306:01EDGAR2Form 8-K - Current report
12/05/202321:52GLOBEArvinas to Host Conference Call and Webcast to Discuss..
12/05/202312:33GLOBEArvinas and Pfizer Announce Interim Data from Phase 1b Trial..
11/28/202316:05GLOBEArvinas and Pfizer Announce Updated Vepdegestrant (ARV-471)..
11/27/202306:11EDGAR2Form 8-K - Current report
11/27/202306:00GLOBEArvinas Announces Oversubscribed $350 Million Private..
11/07/202316:24EDGAR2Form S-3ASR - Automatic shelf registration statement of..
11/07/202315:27EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
11/07/202306:03EDGAR2Form 8-K - Current report
11/07/202306:00GLOBEArvinas Reports Third Quarter 2023 Financial Results and..
11/02/202306:00GLOBEArvinas to Participate in Upcoming Investor Conferences
10/23/202307:30EDGAR2Form 8-K - Current report
10/22/202306:00GLOBEPotential of Arvinas’ PROTAC® AR Degraders Reinforced by..
10/18/202306:00GLOBEArvinas Gives Back to Local Greater New Haven Community in..
10/15/202317:07GLOBEArvinas Announces Upcoming Bavdegalutamide Poster..
10/15/202317:05GLOBEArvinas and Pfizer Announce Upcoming Vepdegestrant (ARV-471)..
9/01/202306:00GLOBEArvinas to Participate in Upcoming Investor Conferences
8/14/202316:27EDGAR2Form 4 - Statement of changes in beneficial ownership of..
8/08/202315:09EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
8/08/202306:03EDGAR2Form 8-K - Current report
8/08/202306:00GLOBEArvinas Reports Second Quarter 2023 Financial Results and..
7/31/202315:30GLOBEArvinas and Pfizer Awarded Innovation Passport Designation..
7/06/202308:00GLOBECarrick Therapeutics Announces Clinical Trial Collaboration..
6/15/202315:30GLOBEArvinas Announces Changes to its Board of Directors
6/08/202306:00GLOBEArvinas Announces Interim Data from the ARV-766 Phase 1/2..
6/05/202306:00GLOBEArvinas to Participate in Upcoming Investor Conferences
5/08/202306:00GLOBEArvinas and Pfizer Announce Upcoming Vepdegestrant (ARV-471)..

Your Recent History

NASDAQ
ARVN
Arvinas
Delayed Upgrade Clock
ADVFN Logo

Canada
Company
Business
Popular
Get The App

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved